Amorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based Therapeutics

Pipeline of Disease-Modifying Therapies Targets Hypoparathyroidism, Pancreatic Cancer, osteoporotic fractures, and Crohn's Disease

NES ZIONA, Israel, Sept. 2, 2025 /PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben as its Chief Executive Officer. Ben will guide the company forward as it accelerates its regulatory pathway strategy in the U.S. and Europe, and advances its pipeline of disease-modifying therapeutics.

With his strong foundation in biomedical engineering and management, Ben will drive Amorphical's strategy to convert nature-inspired discoveries into high-value pharmaceutical assets. Central to this effort is the company's proprietary nano-amorphous mineral technology, which uniquely regulates cellular pH and delivers superior bioavailability. These competitive advantages fuel a diversified clinical pipeline addressing significant unmet needs in oncology, metabolic and endocrine disorders, and musculoskeletal health - disease areas with substantial market opportunity and global impact.

"Our nano-amorphous mineral technology, which is more than a million times smaller than conventional mineral forms, represents a new frontier in medicine and allows us to move beyond symptom management toward true disease-modifying therapies," said Eden Ben, CEO of Amorphical. "We are committed to delivering a safe and effective nano-mineral platform that we hope will address many indications for patients worldwide."

Amorphical enters clinical development with more than a decade of real-world experience gained through early access and compassionate use programs. These experiences provide insight into safety, tolerability, and patient-reported outcomes, guiding the company's clinical strategy and regulatory pathway. Current studies include a Phase 2 trial for hypoparathyroidism, which is being conducted under the FDA, with additional studies for pancreatic cancer, osteoporotic fractures, and Crohn's disease under regulatory review.

The company's pharmaceutical-grade infrastructure, including a multi-certified and GMP-compliant facility, provides the foundation to accelerate the development of its therapeutic pipeline and bring new scientifically validated treatments to market.

"Eden's deep expertise is perfectly aligned with Amorphical's operational priority to deliver safe, effective, and breakthrough nano-amorphous mineral treatments for a variety of serious diseases," said Ran Gorelik, Member of the Board of Directors at Amorphical. "His appointment marks a critical step as we accelerate development, regulatory, and clinical milestones to unlock the great potential of our clinical approach to treating disease symptoms and their root causes."

About Amorphical

Amorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims to address unmet needs in areas like pancreatic cancer, inflammatory diseases and metabolic disorders by enhancing bioavailability and optimizing pH balance at the cellular level. Supported by nearly 200 patents, extensive real-world exposure, and a GMP-certified manufacturing infrastructure, Amorphical is committed to bringing scientifically validated, disease-modifying mineral therapies to patients.
Learn more at www.amorphical.com and follow Amorphical on LinkedIn.

Media Contact: 
Ellie Hanson
FINN Partners for Amorphical
[email protected]
+1-929-588-2008

SOURCE Amorphical